A retrospective study assessing the choice of Glecaprevir/pibrentasvir and sofosbuvir/velpatasvir and its impact on SVR rates in patients with Hepatitis-C infection
Latest Information Update: 21 Oct 2020
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary) ; Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 21 Oct 2020 New trial record
- 29 Aug 2020 Results presented at The International Liver Congress 2020